Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Jia Yao, Shaobo Pan, Xiao Fan, Xue Jiang, Yuhong Yang, Jing Jin & Yu Liu. (2020) Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II–III locally advanced breast cancer. Journal of Chemotherapy 32:4, pages 202-207.
Read now
Read now
Silvia Antolín, Benigno Acea, Luis Albaina, Ángel Concha, Paz Santiago, Tomás García-Caballero, Joaquín J Mosquera, José Ramón Varela, Rafaela Soler & Lourdes Calvo. (2019) Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution. Breast Cancer: Targets and Therapy 11, pages 29-42.
Read now
Read now
Yu-Tuan Wu, Zhou Xu, Ke Zhang, Jiu-song Wu, Xin Li, Bilal Arshad, Ying-Cun Li, Zhong-Liang Wang, Hong-Yuan Li, Kai-Nan Wu & Ling-Quan Kong. (2018) Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis. Therapeutics and Clinical Risk Management 14, pages 1789-1797.
Read now
Read now
Yesenia L Franco, Tanaya R Vaidya & Sihem Ait-Oudhia. (2018) Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer. Breast Cancer: Targets and Therapy 10, pages 131-141.
Read now
Read now
Stig Larsen, Kritiya Butthongkomvong, Alexey Manikhas, Ekaterina Trishkina, Elena Poddubuskaya, Marina Matrosova, Vichien Srimuninnimit & Steen Lindkær-Jensen. (2014) BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase. Breast Cancer: Targets and Therapy 6, pages 179-189.
Read now
Read now
Articles from other publishers (5)
Silvia Dellapasqua, Pamela Trillo Aliaga, Elisabetta Munzone, Vincenzo Bagnardi, Eleonora Pagan, Emilia Montagna, Giuseppe Cancello, Raffaella Ghisini, Claudia Sangalli, Mara Negri, Manuelita Mazza, Monica Iorfida, Anna Cardillo, Angela Sciandivasci, Nadia Bianco, Ana Paula De Maio, Monica Milano, Giuseppe Maria Campennì, Loredana Sansonno, Giuseppe Viale, Anna Morra, Maria Cristina Leonardi, Viviana Galimberti, Paolo Veronesi & Marco Colleoni. (2021) Pegylated Liposomal Doxorubicin (Caelyx®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial. Current Oncology 28:6, pages 5167-5178.
Crossref
Crossref
Jin Zhang, Hongchuan Jiang, Jian Zhang, Guoqiang Bao, Guoqiang Zhang, Haibo Wang & Xi Wang. (2021) Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study. BMC Cancer 21:1.
Crossref
Crossref
Chih-Chiang Hung, Youngsen Yang, I-Chen Tsai, Chiann-yi Hsu, Chia-Hua Liu & Jie-Ru Yang. (2020) The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan. Biochemistry Research International 2020, pages 1-9.
Crossref
Crossref
Ming Zhao, Xian-feng Ding, Jian-yu Shen, Xi-ping Zhang, Xiao-wen Ding & Bin Xu. (2017) Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice多柔比星脂质体在乳腺癌辅助化疗中的临床应用. Journal of Zhejiang University-SCIENCE B 18:1, pages 15-26.
Crossref
Crossref
Anuradha Subramanian, Amrutha Manigandan, Sivashankari P.R.Swaminathan Sethuraman. (2015) Development of nanotheranostics against metastatic breast cancer — A focus on the biology & mechanistic approaches. Biotechnology Advances 33:8, pages 1897-1911.
Crossref
Crossref